# US 2018/0021251 A1 · Stimulation of appetite and treatment of anorexia in dogs and cats

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021251 A1
- Document ID: US20180021251A1
- Status: Published application
- Kind: A1
- Application number: 15/551,847
- Filed: 2016-02-26
- Published: 2018-01-25
- Earliest claimed: 2015-02-27
- Assignees: Kindred Biosciences, Inc.
- Applicants: Kindred Biosciences, Inc.
- Inventors: William Buhles; Richard Cortez; Kristin Maas; Geeta Srivastava; Daniel Perez
- Web page: https://patentgrep.com/patent/US20180021251A1

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0017: {Non-human animal skin, e.g. pour-on, spot-on}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutical formulations and methods useful for the treatment of anorexia and the stimulation of appetite and weight gain, and the management of weight loss in dogs and cats.

## Claims

### Claim 1

A pharmaceutical formulation for the treatment of anorexia and stimulation of appetite and management of weight loss in dogs and cats said formulation comprising a therapeutically effective dose of mirtazapine for topical administration by transdermal absorption.

### Claim 2 (depends on 1)

The pharmaceutical formulation of claim 1, wherein said formulation is an ointment.

### Claim 3 (depends on 1, 2)

The pharmaceutical formulation of claim 1 or claim 2 wherein at least one component of the formulation is a solubilizer.

### Claim 4 (depends on 1, 2, 3)

The pharmaceutical formulation of any one of claims 1 to 3 wherein at least one component is a penetration enhancer.

### Claim 5 (depends on 1, 2, 3, 4)

The pharmaceutical formulation of any one of claims 1 to 4 that comprises both a penetration enhancer and solubilizer.

### Claim 6 (depends on 5)

The pharmaceutical formulation of claim 5 that contains at least 25% by weight of said mixture of penetration enhancer and solubilizer.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The pharmaceutical formulation of any one of claims 1 to 6, which is selected from the group consisting of Formulation G, Formulation H incorporating Dry-Flo AF, Formulation H incorporating Dry-Flo TS, Formulation O, Formulation T incorporating Dry-Flo AF, and Formulation T incorporating Dry-Flo TS.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A method of applying the formulation of any one of claims 1 to 7 comprising topically administering onto the skin of a dog or cat a dose of such formulation sufficient to result in transdermal absorption of a therapeutically effective dose of mirtazapine from the surface of the skin into the systemic circulation.

### Claim 9 (depends on 8)

The method of claim 8 wherein the dosage of mirtazapine administered in a single daily dose is in the range of 0.05 to 2 mg/kg of weight of the dog or cat to be treated.

### Claim 10 (depends on 8, 9)

The method of claim 8 or claim 9 wherein the ointment placed onto the skin is applied in a volume of 0.05 to 5.0 ml per dose.

### Claim 11 (depends on 8)

The method of claim 8 wherein the dose administered is between 0.2 and 5 mg per cat, or between 0.5 and 50 mg per dog.

### Claim 12 (depends on 8, 9, 10, 11)

The method of any one of claims 8 to 11, wherein the dosage form generally provides peak blood plasma levels of mirtazapine in a range of 10 ng/ml to 150 ng/ml, or 10 ng/ml to 120 ng/ml, or 10 ng/ml to 100 ng/ml, or 10 ng/ml to 60 ng/ml, or 10 ng/ml to 30 ng/ml.

### Claim 13 (depends on 8, 9, 10, 11, 12)

The method of any one of claims 8 to 12, wherein the dosage form generally provides blood plasma levels of mirtazapine of at least 10 ng/ml for at least 6 hours during the 24 hour period immediately following application of the formulation to the pinna, or in a range of 10 ng/ml to 30 ng/ml for at least 6 to 12 hours during the 24 hour period immediately following application of the formulation to the pinna.

### Claim 14 (depends on 8, 9, 10, 11, 12, 13)

The method of any one of claims 8 to 13, wherein the dosage form generally provides an AUC of mirtazapine in the range of 450-650 h*ng/ml per dose, or in the range of 300 to 1200 h*ng/ml in the 24 hour period immediately following application of the formulation to the pinna, or in the range of 300 to 1000 h*ng/ml in the 24 hour period immediately following application of the formulation to the pinna.

### Claim 15 (depends on 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 8 to 14 wherein the said dog or cat is suffering from anorexia, weight loss, decreased body condition score secondary to renal failure, hepatopathy, the results of surgery, dental disease, neoplasia, old age, or other acute or chronic condition.

### Claim 16 (depends on 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 8 to 15 wherein the dose is applied once daily, or every other day, or once weekly, or once every 2 weeks, or monthly.

### Claim 17 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 8 to 16 wherein the dose is applied for 1 week, including for 2, 3, or 4 weeks, including for 2, 3, 4, 5 or 6 months.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7)

The pharmaceutical formulation of any one of claims 1 to 7 wherein the formulation is provided in a container which protects the formulation from moisture, air, and/or light.

### Claim 19 (depends on 18)

The pharmaceutical formulation of claim 18, wherein the container is a device capable of dispensing a volume of drug product in a range of between 0.05 and 2.0 mL repeatedly and consistently by activation of the device by the user.

### Claim 20

A method of treating anorexia, stimulating appetite, and/or managing weight loss in a dog or cat, comprising applying an ointment comprising a therapeutically effective dose of mirtazapine for topical administration by transdermal absorption onto the skin of the dog or cat.

### Claim 21 (depends on 20)

The method of claim 20, wherein the applying results in transdermal absorption of a therapeutically effective dose of mirtazapine from the surface of the skin into the systemic circulation.

### Claim 22 (depends on 20, 21)

The method of claim 20 or claim 21, wherein the dosage of mirtazapine administered in a single daily dose is in the range of 0.05 to 2 mg/kg of weight of the dog or cat to be treated.

### Claim 23 (depends on 20, 21, 22)

The method of any one of claims 20 to 22, wherein the ointment is applied in a volume of 0.05 to 2.0 ml per dose.

### Claim 24 (depends on 20, 21, 22, 23)

The method of any one of claims 20 to 23, wherein the dose administered is between 0.2 and 5 mg per cat, or between 0.5 and 50 mg per dog.

### Claim 25 (depends on 20, 21, 22, 23, 24)

The method of any one of claims 20 to 24, wherein the ointment provides peak blood plasma levels of mirtazapine in a range of 10 ng/ml to 150 ng/ml, or 10 ng/ml to 120 ng/ml, or 10 ng/ml to 100 ng/ml, or 10 ng/ml to 60 ng/ml, or 10 ng/ml to 30 ng/ml.

### Claim 26 (depends on 20, 21, 22, 23, 24, 25)

The method of any one of claims 20 to 25, wherein the ointment provides blood plasma levels of mirtazapine of at least 10 ng/ml for at least 6 hours during the 24 hour period immediately following application of the formulation to the pinna, or in a range of 10 ng/ml to 30 ng/ml for at least 6 to 12 hours during the 24 hour period immediately following application of the ointment to the skin.

### Claim 27 (depends on 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 20 to 26, wherein the ointment is applied to the pinna.

### Claim 28 (depends on 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 20 to 27, wherein the ointment generally provides an AUC of mirtazapine in the range of 450-650 h*ng/ml per dose, or in the range of 300 to 1200 h*ng/ml in the 24 hour period immediately following application of the formulation to the pinna, or in the range of 300 to 1000 h*ng/ml in the 24 hour period immediately following application of the formulation to the pinna.

### Claim 29 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 20 to 28, wherein the ointment comprises a solubilizer.

### Claim 30 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 10 to 29, wherein the ointment comprises a penetration enhancer.

### Claim 31 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 20 to 30, wherein the ointment comprises a penetration enhancer and solubilizer.

### Claim 32 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 20 to 31, wherein the ointment contains at least 25% by weight total of penetration enhancer and solubilizer.

### Claim 33 (depends on 29, 31)

The method of claim 29, 31, or 32, wherein the solubilizer is selected from DGME, Labrasol®, and oleyl alcohol.

### Claim 34 (depends on 30, 31, 32, 33)

The method of any one of claims 30 to 33, wherein the penetration enhancer is selected from Di-ethylene Glycol Monoethyl Ether (DGME) and PEG-8 Caprylic/Capric Glycerides (Labrasol®).

### Claim 35 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 20 to 32, wherein the ointment is selected from the group consisting of Formulation G, Formulation H incorporating Dry-Flo AF, Formulation H incorporating Dry-Flo TS, Formulation O, Formulation T incorporating Dry-Flo AF, and Formulation T incorporating Dry-Flo TS.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 18)

The pharmaceutical formulation of any one of claims 1 to 7, 18, and 19, wherein the formulation comprises 20-80%, or 20-70%, or 30-80%, or 30-70%, or 40-80%, or 40-70%, or 50-80%, or 50-70% of polyethylene glycols.

### Claim 37 (depends on 36)

The pharmaceutical formulation of claim 36, wherein the polyethylene glycols include one or more of polyethylene glycol 400, polyethylene glycol 3350, polyethylene glycol 4000, polyethylene glycol 2000, or polyethylene glycol 6000.

### Claim 38 (depends on 37)

The pharmaceutical formulation of claim 37, wherein the polyethylene glycols include polyethylene glycol 400.

### Claim 39 (depends on 37, 38)

The pharmaceutical formulation of claim 37 or claim 38, wherein the polyethylene glycols include polyethylene glycol 3350.

### Claim 40 (depends on 37, 38, 39)

The pharmaceutical formulation of any one of claims 37 to 39, wherein the polyethylene glycols include polyethylene glycol 400 and polyethylene glycol 3350.

### Claim 41 (depends on 40)

The pharmaceutical formulation of claim 40, wherein the formulation comprises 30-50% polyethylene glycol 400 and 10-30% polyethylene glycol 3350.

### Claim 42 (depends on 41)

The pharmaceutical formulation of claim 41, wherein the formulation comprises 30-45% polyethylene glycol 400 and 20-25% polyethylene glycol 3350.

### Claim 43 (depends on 36, 37, 38, 39, 40, 41, 42)

The pharmaceutical formulation of any one of claims 36 to 42, wherein the formulation comprises 15-25% diethylene glycol monoethyl ether (DGME).

### Claim 44 (depends on 36, 37, 38, 39, 40, 41, 42, 43)

The pharmaceutical formulation of any one of claims 36 to 43, wherein the formulation comprises 5-10% PEG-8 caprylic/capric glycerides.

### Claim 45 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44)

The pharmaceutical formulation of any one of claims 36 to 44, wherein the formulation comprises 3-8% oleyl alcohol.

### Claim 46 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The pharmaceutical formulation of any one of claims 36 to 45, wherein the formulation comprises 0.5-3% polydimethylsiloxane fluid.

### Claim 47 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The pharmaceutical formulation of any one of claims 36 to 46, wherein the formulation comprises 1-4% Tapioca Starch Polymethylsilsequioxane (Dry Flo TS).

### Claim 48 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The pharmaceutical formulation of any one of claims 36 to 47, wherein the formulation does not comprise ethanol.

### Claim 49 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The pharmaceutical formulation of any one of claims 36 to 48, wherein the formulation does not comprise hydroxypropylcellulose.

### Claim 50 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 8 to 17 and 20 to 35, wherein the formulation comprises 20-80%, or 20-70%, or 30-80%, or 30-70%, or 40-80%, or 40-70%, or 50-80%, or 50-70% of polyethylene glycols.

### Claim 51 (depends on 50)

The method of claim 50, wherein the polyethylene glycols include one or more of polyethylene glycol 400, polyethylene glycol 3350, polyethylene glycol 4000, polyethylene glycol 2000, or polyethylene glycol 6000.

### Claim 52 (depends on 51)

The method of claim 51, wherein the polyethylene glycols include polyethylene glycol 400.

### Claim 53 (depends on 50, 51)

The method of claim 50 or claim 51, wherein the polyethylene glycols include polyethylene glycol 3350.

### Claim 54 (depends on 50, 51, 52)

The method of any one of claims 50 to 52, wherein the polyethylene glycols include polyethylene glycol 400 and polyethylene glycol 3350.

### Claim 55 (depends on 54)

The method of claim 54, wherein the formulation comprises 30-50% polyethylene glycol 400 and 10-30% polyethylene glycol 3350.

### Claim 56 (depends on 54)

The method of claim 54, wherein the formulation comprises 30-45% polyethylene glycol 400 and 20-25% polyethylene glycol 3350.

### Claim 57 (depends on 50, 51, 52, 53, 54, 55, 56)

The method of any one of claims 50 to 56, wherein the formulation comprises 15-25% diethylene glycol monoethyl ether (DGME).

### Claim 58 (depends on 50, 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 50 to 57, wherein the formulation comprises 5-10% PEG-8 caprylic/capric glycerides.

### Claim 59 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 50 to 58, wherein the formulation comprises 3-8% oleyl alcohol.

### Claim 60 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 50 to 59, wherein the formulation comprises 0.5-3% polydimethylsiloxane fluid.

### Claim 61 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The method of any one of claims 50 to 60, wherein the formulation comprises 1-4% Tapioca Starch Polymethylsilsequioxane (Dry Flo TS).

### Claim 62 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 50 to 61, wherein the formulation does not comprise ethanol.

### Claim 63 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method of any one of claims 50 to 62, wherein the formulation does not comprise hydroxypropylcellulose.
